The Rationale Behind CheckMate-275 in Metastatic Bladder Cancer

October 11, 2016
Matthew Galsky, MD

Matthew Galsky, MD, professor of Medicine, Mount Sinai School of Medicine, discusses the significant findings in, and the rationale behind conducting the CheckMate-275 trial during an interview at the 2016 ESMO Congress.